protocadherin gamma subfamily A, 12Genealiases: CDH21 · FIB3 · PCDH-GAMMA-A12
Q-omics provides the consensus-scored PCDHGA12 profile across patient tissues and cancer cell-line models. PCDHGA12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCDHGA12 is differentially expressed in 14, with the highest sampling consensus in UCEC. Additionally, PCDHGA12 RNA expression shows 18,050 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, UCEC, and THYM as cancer lineages where PCDHGA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHGA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHGA12 survival associations across molecular data types. PCDHGA12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHGA12 RNA expression–survival associations across cancer types. High PCDHGA12 expression shows unfavorable associations in KIRP, LUSC and UVM, but favorable associations in KIRC, MESO and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCDHGA12 RNA expression.
This table summarizes PCDHGA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCDHGA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHGA12 shows lower tumor expression in UCEC, KICH, LUAD, BLCA, LUSC and BRCA. The UCEC box plot shows higher PCDHGA12 RNA expression in normal versus tumor tissue (log2 FC = −1.291, t-test p < 0.001).
This table shows molecular features associated with PCDHGA12 in patient tissues and cancer cell lines. In patient samples, PCDHGA12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHGA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
